Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
In my view, this RNS confirms that SRA 737 is still on while we close down the administrative issues on 1801. This is a positive RNS from the board to confirm to the market that nothing is lost with GSK not progressing with it.
with 2-3 trades you can take the share price wherever you want. the only thing needed to restore confidence, in absence of RNS, is Director's buy. Unsure if they are allowed during this period when you are expecting some results.
Agree it is not the right outcome as everyone was expecting it to be a formality. However the RNS clearly states that the application has not been approved in absence of some artefacts/information. It nowhere means "Rejection". Also we must understand that the trials have not failed which would have been disastrous, as was case in SNG. It is a simple case of missing information/further queries. Surely the share price would see fall tomorrow as slightest negative news is punished badly but buying should come in thereafter to stabilise the share price. I am hoping Directors buy and send signal of confidence. ATB
We should worry if the product failed but nowhere that is the case. 737 was returned and there could be multitude of reason behind that but not the efficacy of the product. what if it was still sitting with SO, would that have given us more direction/clarity or now when we know that 737 is back to the owner.
Have faith and bring some positivity if you all are investors.
Reading the recent posts, it seems many people are happy here that SAR has been butchered. Still fail to understand why would someone bad mouth a share they are invested in. If you are not invested, why are you wasting your time on this board ?
I am surprised that people were expecting GSK to mention SRA737 in the update. Don't think they have gone to that level of details in the RNS. There is small mention of Sierra acquisition which they have to do anyway. Guess we are reading too much into it. Strong hold for me. GLA